Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318399 | 0.82 | FLT3 (0.42) | FLT3MERTKGAS6 | |
| SCHEMBL27833136 | 0.81 | FLT3 (0.37) | FLT3MERTKGAS6 | |
| SCHEMBL23106917 | 0.81 | FLT3 (0.43) | FLT3MERTKGAS6 | |
| SCHEMBL3317954 | 0.79 | GRM2 (0.39) | FLT3HRH3GRM2TNKSPARP1 | |
| SCHEMBL3321202 | 0.78 | GRM2 (0.50) | HRH3GRM2TNKSPARP1PARP6 | |
| SCHEMBL23103351 | 0.78 | FLT3 (0.41) | FLT3MERTKGAS6HRH3 | |
| SCHEMBL1126385 | 0.76 | NAMPT (0.46) | FLT3MERTKGAS6NAMPTHDAC3 | |
| SCHEMBL3318608 | 0.76 | HRH3 (0.41) | HRH3GRM2TNKSPARP1PARP6 | |
| SCHEMBL27833137 | 0.75 | FLT3 (0.39) | FLT3MERTKGAS6KMT2AACHE | |
| SCHEMBL518379 | 0.72 | ALDH1A1 (0.44) | FLT3MERTKGAS6MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | claimed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| US-8815901-B2 | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-8273882-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FLT3 21/4885MERTK 975/4885GAS6 4293/4885 |
| US-20130324519-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FLT3 5/4885MERTK 250/4885GAS6 3196/4885 |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FLT3 5/4885MERTK 250/4885GAS6 3196/4885 |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | FLT3 5/4885MERTK 250/4885GAS6 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.